Investment analysts at StockNews.com assumed coverage on shares of Minerva Neurosciences (NASDAQ:NERV – Get Free Report) in a research report issued to clients and investors on Monday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.
Separately, HC Wainwright decreased their price target on Minerva Neurosciences from $7.00 to $5.00 and set a “neutral” rating for the company in a research note on Wednesday, August 7th.
Read Our Latest Stock Report on Minerva Neurosciences
Minerva Neurosciences Stock Up 0.1 %
Minerva Neurosciences (NASDAQ:NERV – Get Free Report) last issued its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported ($1.09) EPS for the quarter, missing the consensus estimate of ($0.97) by ($0.12). As a group, analysts expect that Minerva Neurosciences will post -2.26 EPS for the current year.
About Minerva Neurosciences
Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.
Featured Stories
- Five stocks we like better than Minerva Neurosciences
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- 3 Stocks That Could Rise on European Bank Interest Rate Cuts
- How Investors Can Find the Best Cheap Dividend Stocks
- Take Advantage of Village Farms Stock as Cannabis Market Evolves
- Conference Calls and Individual Investors
- MarketBeat Week in Review – 9/16 – 9/20
Receive News & Ratings for Minerva Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.